ALLR
Allarity Therapeutics, Inc.
Key Financials
Net Income
$-11231000
↑ 54.2%
Operating Income
$-12605000
↑ 53.7%
Gross Profit
$-2265000
N/A
EPS (Diluted)
$-10.26
↓ 364.3%
Total Assets
$18.3M
↓ 19.4%
Total Liabilities
$8.4M
↓ 22.2%
Cash & Equivalents
$14.7M
↓ 24.8%
Long-term Debt
$2.7M
↑ 1.6%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| PRE 14A | 4/10/2026 | View on SEC |
| 8-K | 4/1/2026 | View on SEC |
| 10-K | 3/30/2026 | View on SEC |
| 8-K | 3/9/2026 | View on SEC |
| 8-K | 3/6/2026 | View on SEC |
| 8-K | 2/19/2026 | View on SEC |
| S-3 | 2/12/2026 | View on SEC |
| 8-K | 2/4/2026 | View on SEC |
| 424B5 | 1/29/2026 | View on SEC |
| 8-K | 1/29/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ALLR |
| Company Name | Allarity Therapeutics, Inc. |
| CIK | 1860657 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 401-426-4664 |